Vaginal Cancer - Pipeline Review, H2 2017 - Research and Markets Print
Business Wire
Thursday, 07 December 2017 07:06
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Women's Health, Cervical Cancer Drugs
Dec. 7, 2017 17:48 UTC

Vaginal Cancer - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)-- The "Vaginal Cancer - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Vaginal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vaginal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 1 and 1 respectively.

Vaginal Cancer (Oncology) pipeline guide helps in identifying and

tracking emerging players in the market and

Error. Page cannot be displayed. Please contact your service provider for more details. (8)

their portfolios, enhances decision making capabilities and
helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Vaginal Cancer - Overview
  3. Vaginal Cancer - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Vaginal Cancer - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Vaginal Cancer - Companies Involved in Therapeutics Development
  • ISA Pharmaceuticals BV
  • MedImmune LLC
  • Ology Bioservices Inc
  • Ono Pharmaceutical Co Ltd
  • Oryx GmbH & Co KG
  • Taiwan Liposome Company Ltd

For more information about this report visit https://www.researchandmarkets.com/research/t2bsmh/vaginal_cancer?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Women's Health, Cervical Cancer Drugs


Source: Research and Markets




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1